RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death.
22 Jul, 2021 | 11:08h | UTCCommentary: Dapagliflozin in patients with COVID-19: truth or dare – The Lancet Diabetes & Endocrinology